Fibroids and tamoxifen

swimjames

[Expansive uterine myoma during tamoxifen therapy. 11 cases].

Abstract

Tamoxifen, a non-steroid anti-oestrogen derivative of diethylstilboestrol, is the main drug used for hormone therapy for hormone-dependent breast cancer. This ambivalent drug has both antagonist and agonist effects. While tamoxifen blocks tumour growth it can also have an undesirable agonist effect on the genital tract. The uterus is a target organ for this paradoxical action due to proestrogenic stimulation of the endometrium and the myometrium. We observed eleven cases of uterine fibromyoma during treatment with tamoxifen which required hysterectomy due to increased tumour volume. The pathology report on the surgical specimens did not show any evidence of malignancy. Differential diagnosis is based on sarcomatous degeneration of the fibromyoma and presence of intra-myomatous metastases from the breast. Hysterectomy is indicated in menopaused patients with a symptomatic fibromyomatous uterus before starting long-term anti-oestrogen therapy for hormone-dependent breast cancer.

PMID:

8545398

Indexed for MEDLINE]

New Answer for Tamoxifen Problem

FROM THE WEBMD ARCHIVES

---

---

swimjames

New Answer for Tamoxifen Problem

FROM THE WEBMD ARCHIVES

Nov. 16, 2000 -- A birth control device is being tested as a way to protect women from dangerous side effects associated with a common breast cancer drug.

Tamoxifen is one of the most effective and widely used medications doctors can give women battling breast cancer. In studies, tamoxifen has been shown to help prevent recurrences of breast cancer when taken for five years after surgery. It also is being researched as a way of preventing breast cancer in women at high risk for the disease.

Tamoxifen can cause vaginal bleeding and stimulate growths in the endometrium, the lining of the uterus. The new findings are important because changes in the uterus -- though not always serious -- are fairly common among women taking tamoxifen to treat breast cancer.

"A third of women [taking tamoxifen] will develop either polyps or endometrial [growths] over five years, and there is approximately a three-times increased risk of endometrial cancer," says Francis Gardner, MD, of the University of Leicester in the U.K.

In a study of 113 postmenopausal women who had taken tamoxifen for at least one year, Gardner randomly fitted about half of them with an IUD, a birth control device placed in the uterus. The remaining women did not receive an IUD, but all 113 women received special exams over a one-year period to check for changes in the endometrium. The study appears in Friday's issue of The Lancet.

After one year, women who had the IUD had no new growths and 13% fewer fibroids than women who did not get the IUD, according to Gardner. Also, those who had the IUD showed no change in the uterus.

The IUD releases small amounts of the hormone levonorgestrel every day. Like other IUD's, the one used in the study is intended for birth control, but the researchers theorize that levonorgestrel, which is a progestagen, may protect the lining of the uterus from overgrowing in response to tamoxifen.

One expert says the approach makes sense, but he questions whether all women who take tamoxifen should be using the IUD to protect against endometrial changes. Patrick Neven, MD , suggests that the IUD may only be justified for women who already have had such changes.

Neven, of the Kliniek St-Jan in Brussels, Belgium, also points out that while the IUD has been widely tested in young women as a means of preventing pregnancy, it hasn't been thoroughly tested in older women, and the long-term effects of the IUD's hormone are unknown.

Currently, the benefits of tamoxifen for selected women are thought to outweigh the risk of endometrial changes. If such changes develop, the women must undergo testing of a sample of the endometrium even though most tests don't find evidence of cancer. If proven effective in future studies, the IUD would increase confidence of doctors and patients that the uterus is protected while taking tamoxifen without bringing them in for frequent checkups.

"These women have already undergone major surgery for their breastcancer, and they're also subjected to repeated investigations to exclude endometrial [cancers]," Gardner says. "If we can use this device and fit it to women around the time of diagnosis, then we are confident that it should be effective in preventing ... [growths] and cancer," he says.

To confirm that assumption, Gardner says the next step is to insert the IUD in women who are just beginning tamoxifen therapy. The women will use the IUD for the full five years that they are on tamoxifen and be monitored for any changes in their uterus.

ksusan

1995 for the first article. I imagine it depends on number and size of fibroids, but 3 gynecologists and my MO did not suggest a hysterectomy for pre-existing fibroids before Tamoxifen.

The 2000 study would be interesting to see a follow-up on. One year doesn't seem long enough except as a preliminary report, and I'd hesitate to put a device containing a progestogen in my uterus.

swimjames

From Dr. Naven:

Many thanks for the e mail and sorry to hear you have been diagnosed with breast cancer.

If it is a hormone receptor positive breast cancer than that is good news as these are easier to treat than the estrogen receptor negative ones. Tamoxifen is an anti-estrogen with estrogen properties in the uterus but the side effect of endometrial cancer is about 1 extra per 1000 per year of use. So don't remove the uterus unless there is another reason. We almost always give sequential combinations of tamoxifen and aromatase inhibitor to prevent relapses. I don't know your breast cancer features but think this is the best approach. The LNG-loaded coil (Mirena) is increasing the breast cancer incidence in women who never had breast cancer a little bit, so not a good solution!

Best regards

Patrick Neven